Table 2.
Cancer Clinical Trials Knowledge Items (n=127)
| Fall Sample (n = 127) | Race (n = 125) | Ethnicity1 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Correct Answer | Correct N (%) | White (n = 55) | African-American (n = 15) | Asian (n = 34) | Mixed Race (n = 7) | Other Race (n = 14) | Latino (n = 19) | Non-Latino (n = 106) | |
| In a cancer treatment trial, patients will receive a placebo or the new treatment being tested | False | 45 (35.4%) | 28 (50.9%) | 6 (40%) | 7 (20.6) | 3 (42.9%) | 1 (7.1%) | 5 (26.3%) | 40 (37.7%) |
| The new approach being tested in a cancer treatment trial is superior to the standard treatment. | False | 60 (47.2%) | 34 (61.8%) | 4 (26.7%) | 16 (47.1) | 3 (42.9%) | 3 (21.4%) | 8 (42.1%) | 52 (49.1%) |
| About 15% of all U.S. adults with cancer participate in cancer treatment trials. | False | 11 (8.7%) | 5 (9.1%) | 1 (6.7%) | 2 (5.9) | 1 (14.3%) | 2 (14.3%) | 1 (5.3%) | 10 (9.4%) |
| The rate of U.S. adults who participate in cancer treatment trials is lower among minority groups and the medically underserved. | True | 88 (69.3%) | 38 (69.1%) | 14 (93.3) | 20 (58.8%) | 7 (100%) | 7 (50%) | 15 (78.9%) | 73 (68.9%) |
| Most cancer patients are told about the option of receiving care through a treatment trial, but they decide not to do so. | False | 39 (30.7%) | 20 (36.4%) | 6 (40%) | 8 (23.5%) | 1 (14.3%) | 3 (21.4%) | 2 (10.5%) | 37 (34.9%) |
| Cancer treatment trials are best reserved as the last resort for patients who have no other treatment options. | False | 78 (61.4%) | 39 (70.9%) | 12 (80%) | 17 (50%) | 4 (57.1%) | 4 (28.6%) | 10 (52.6%) | 67 (63.2%) |
| All cancer treatment trials in the U.S. are subject to federal regulations that protect patients' rights and safety. | True | 115 (90.6%) | 48 (87.3%) | 15 (100%) | 30 (88.2%) | 7 (100%) | 13 (92.9%) | 18 (94.7%) | 96 (90.6%) |
| Total Percent Correct (M, SD) | 49% (23) | 56% (24) | 55% (12) | 42% (24) | 53% (23) | 33% (18) | 44% (18) | 50% (.24) | |
1
Two missing data